Wednesday 25th January, 2017
08.00 Registration & Networking
08.50 Chair’s Opening Remarks
Seizing the Microbiome: Can We Sort the Hype from the Hope?
09.00 Perspectives on a Microbiome-Based Industry: How Far Are We From Science to Products?
- Isabelle De Cremoux CEO, Seventure Partners
- What are the most successful microbiome trends with clear therapeutic potential?
- Exploring the current financial perspective in an emerging microbiome based industry
- Why the microbiome industry is set to be bigger than the biotechnology bubble
09.30 Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic
- David Cook Executive Vice President of Research & Development and, Chief Scientific Officer Seres Therapeutics
- Review of approaches to mine microbiological and functional information from human
- clinical trials
- Using mechanistic data and pharmacological models to design and test microbiome drugs
- Discussion of regulatory and CMC considerations for translating microbiome drugs into clinical trials
10.00 EB8010 – A Novel Therapeutic Approach Targeting the Microbiome in Patients With Crohn’s Disease.
- Jai Patel Chief Medical Officer, Enterome
- Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s Disease.
- Independent studies have demonstrated an imbalance of the microbiome with a significant
- increase of E. coli with invasive properties, termed adherent-invasive E. coli (AIEC). These
- AIEC bacteria attach to the gut wall of susceptible patients via the fimbrial adhesion protein
- FimH, and subsequently trigger inflammation by invading and proliferating within the gut wall.
- EB8018 is a novel first-in-class molecule targeted to disarm AIEC bacteria by blocking the FimH adhesion and reducing the subsequent production of inflammatory cytokines in the gut wall.
10.30 Microbial Adaptations of the Microbiome
- Henrik Bjorn Nielsen CSO, Clinical Microbiomics
- Delivering concepts and tools that target microbial integration in the microbiome
- Understanding how persistence probabilities in the microbiome can be learned from longitudinal studies
- Using metatranscriptomics to show microbiome response to new microorganisms
11.00 Morning Refreshments and Speed Networking
Translating the Microbiome: Moving From Observational Science to Evidence-Based Medicine
12.00 Where the Microbiome Will Matter for the Pharmaceutical Industry and Why
- Joseph Petrosino Founder and CSO, Diversigen, Inc
- Positioning in academics and a microbiome start-up, in the largest medical centre in the world, provides a unique perspective on translational microbiome research
- Clear evolution of project design: from retrospective to prospective, from associations to causality
- Critical mass is building for the phase of pharma-based microbiome initiatives
12.30 Human-Microbe Interactions: A Drug Discovery Perspective
- James Brown Director of Computational Biology, GSK
- A deeper dialogue is occurring between infectious and chronic disease disciplines
- The microbiome opens new therapeutic paradigms for many chronic diseases
- The host-pathogen interactome offers new ways for treating infectious diseases
- Using examples from GSK research the translational science of the microbiome and interactome will be discussed
13.00 Development of Pathogen-Specific Antimicrobials to Restore Balance to the Human Microbiome
- Brian Varnum Chief Development Officer, C3-Jian
- Selective antimicrobial peptides remove pathogens and spare the healthy microbiome
- Clinical data support proof of concept for reengineering the oral microbiome
- Clinical experience enables product development innovation
- Advancing to the clinic with targeted antimicrobials for the gut microbiome
13.30 Lunch and Networking
Predicting the Microbiome: Improved Preclinical Models for Drug Discovery
14.30 A Systems Biology Approach to Measuring Human-Microbiome Interactions
- Jens Nielsen Professor Chalmers, University of Technology
- How to use computational platforms to elucidate disease causalities
- Mathematical modelling can be leveraged to understand basic mechanisms in human metabolism
- What are the key disease type mathematical modelling can look to improve?
- Can mathematical models be used to design modulation of the gut microbiome to treat diseases?
15.00 Using Germ-free Mouse Models to Modulate Liver Disease Development
- Philippe Gerard Team Leader, AMIPEM, INRA
- Outlining the key research that validates the influence on the liver by the gut microbiota
- Human gut-microbiota transplants into germ-free suggests that targeting the gut microbiota could be a new therapeutic approach for liver disease management
- Gut microbiota transplants to germ-free mice can be used in the context of other diseases
Build Winning Partnerships to Achieve Holistic Microbiome Success
15.30 Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?
- Kristin Wannerberger Director of R&D Alliance Management, Ferring Pharmaceuticals
- Herve Affagard CEO, Maat Pharma
- Philippe Lenee Director of Partnerships and Technology Transfer, INRA
- James Brown Director of Computational Biology, GSK
- How can we combine Academic knowledge with industrial processes to elucidate
- fundamental mechanisms?
- Outlining the current global successes with establishing microbiome partnerships
- In a multi-functional team of experts, where do we place the key responsibilities?
- How to build a win-win research project in partnership to industrialize microbiome
16.00 Afternoon Refreshments and Networking
16.30 Seizing the Opportunity: Breakout Roundtables
- Jean-Luc Treillous CEO, Laboratories Nutrition et Cardmetabolisme (LNC)
- John Hambor Director, Research Beyond Borders, Boehringer Ingelheim
- Food versus Pharma- Where will the Microbiome have the Maximum Success?
- With successful applications in both nutrition and drug development, which approach will be more successful in short and long term?
- Project Management
- Switching from a medical food mindset to a pharmaceutical mind-set
- Why is there less money invested in the nutrition route?
Jean-Luc Treillou, CEO, Laboratories Nutrition et Cardiometabolism
- Where the Microbiome will Matter for the Pharmaceutical Industry and Why?
- How to apply a pharmaceutical model to an undefined scientific phenomenon?
- Changing your research approaches, clinical design and business models to develop a successful pharma-biotech relationship
- How can big pharma resources be best utilised to accelerate the microbiome R&D?
John Hambor, Director of Research Beyond Borders, Boehringer Ingelheim